share_log

Argus Research Upgrades Silk Road Medical to Buy, Announces $24 Price Target

Benzinga ·  Mar 7 10:43

Argus Research analyst Steve Silver upgrades Silk Road Medical (NASDAQ:SILK) from Hold to Buy and announces $24 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment